Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cancer Vaccines01:30

Cancer Vaccines

321
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
321
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

JCO precision oncology·2026
Same author

Age-related differences in outcomes and tumor characteristics of ultra-rare sarcomas: A Nation-wide Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis.

Liver cancer·2025
Same author

Prognostic significance of positive surgical margins for scalp angiosarcoma.

Journal of the Formosan Medical Association = Taiwan yi zhi·2025

相关实验视频

Updated: May 23, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K

血管肉瘤:免疫疗法的作用

Tom Wei-Wu Chen1,2,3

  • 1Department of Oncology and Center of Excellence for Sarcoma, National Taiwan University Hospital, 7 Chung Shan South Rd, Taipei, Taiwan, 100. tomweiwuchen@ntu.edu.tw.

Current treatment options in oncology
|March 8, 2025
PubMed
概括

免疫检查点抑制剂 (ICI) 在血管肉瘤治疗中显示出不同的结果. 与氨酸激酶抑制剂 (TKI) 的组合显示出希望,而化疗-ICI策略需要进一步研究以获得最佳的患者选择.

关键词:
血管肉瘤是一种血管肉瘤.抗血管原剂是一种抗血管原剂.化疗 化疗是一种化学疗法.免疫检查点抑制剂 免疫检查点抑制剂免疫治疗是一种免疫疗法.瘤基因组学 瘤基因组学

更多相关视频

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

相关实验视频

Last Updated: May 23, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 癌症治疗研究 癌症治疗研究

背景情况:

  • 用免疫检查点抑制剂 (ICI) 治疗血管肉瘤的结果各不相同.
  • 血管肉瘤的亚型对单剂ICI治疗的反应不同,紫外线和辐射相关的类型显示出更高的反应率,可能是由于瘤突变负担 (TMB) 的增加.
  • 双重ICI治疗显示出潜力,但在皮肤血管肉瘤中是有限的.

研究的目的:

  • 审查最近的ICI单独临床试验结果,与氨酸激酶抑制剂 (TKI) 或在血管肉瘤中使用化疗.
  • 评估不同血管瘤亚型的基于ICI的不同治疗策略的疗效和局限性.
  • 确定有前途的治疗组合和未来研究领域,包括生物标志物开发.

主要方法:

  • 审查最近的临床试验调查ICI单疗法,ICI-TKI组合和ICI-化疗组合在血管肉瘤.
  • 从SWOG S1609和联盟A091902等关键试验中分析客观反应率 (ORR) 和无进展生存率 (PFS) 数据.
  • 检查子组分析和解释试验结果的局限性.

主要成果:

  • 单剂ICI (例如,塞米普利马布) 主要有效治疗紫外线和辐射相关的血管瘤.
  • ICI-TKI组合 (例如,卡博桑提尼布加尼沃卢马布) 在皮肤和非皮肤血管瘤中显示出显著的疗效.
  • ICI - 化疗组合显示不一致的结果,一些试验表明在特定子集 (例如,头皮/面部血管肉瘤) 中具有潜在的益处,但缺乏整体PFS改善.

结论:

  • 氨酸激酶抑制剂-ICI组合是血管肉瘤治疗的有前途的策略.
  • 需要进一步完善化疗-ICI策略,包括最佳测序和患者选择.
  • 开发强大的生物标志物对于识别最有可能受益于血管瘤ICI治疗的患者至关重要.